Aurinia Pharmaceuticals Inc. Stock Toronto S.E.
Equities
AUP
CA05156V1022
Biotechnology & Medical Research
Sales 2024 * | 223M 307M | Sales 2025 * | 288M 395M | Capitalization | 696M 956M |
---|---|---|---|---|---|
Net income 2024 * | -6M -8.25M | Net income 2025 * | 58M 79.72M | EV / Sales 2024 * | 1.58 x |
Net cash position 2024 * | 344M 473M | Net cash position 2025 * | 390M 537M | EV / Sales 2025 * | 1.06 x |
P/E ratio 2024 * |
-87.5
x | P/E ratio 2025 * |
12.2
x | Employees | 300 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.55% |
Latest transcript on Aurinia Pharmaceuticals Inc.
Managers | Title | Age | Since |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 93-06-15 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
Robert Foster
FOU | Founder | 65 | 93-06-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 93-06-15 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 19-06-25 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
1st Jan change | Capi. | |
---|---|---|
-3.10% | 102B | |
+2.11% | 96.07B | |
-1.80% | 21.66B | |
-17.75% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.19% | 13.79B | |
+0.18% | 13.33B | |
+19.90% | 10.94B |